Results and Key Takeaways from the Final OS Analysis of the CLEOPATRA Study
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study.
Clinical Pearls
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study. This study looked at first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
- Median OS was 40.8 months in the placebo arm and 56.5 months in the pertuzumab arm – a different of 15.7 months.
- The standard first line treatment for patients with HER2-positive metastatic breast cancer should be pertuzumab, trastuzumab, and a taxane.
- In practice, community oncologists could use paclitaxel instead of docetaxel.
<<<
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
